Article: article from journal or magazin.
Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
Journal of Clinical Psychopharmacology
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Six and seven addicts treated with racemic methadone (MTD) were comedicated with fluvoxamine (FLV) and fluoxetine (FLX), respectively. The plasma concentrations of both (R)- (the active enantiomer) and (S)-MTD were increased by FLV, whereas only (R)-MTD concentrations were increased by the addition of FLX. This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers. The choice of a selective serotonin reuptake inhibitor in depressive addicted patients treated with MTD and the possible use of FLX or FLV to potentiate the effects of MTD in some cases of therapeutic failure are discussed.
Fluoxetine/pharmacokinetics, Fluoxetine/therapeutic use, Fluvoxamine/pharmacokinetics, Fluvoxamine/therapeutic use, Humans, Methadone/pharmacokinetics, Methadone/therapeutic use, Narcotics/pharmacokinetics, Narcotics/therapeutic use, Serotonin Uptake Inhibitors/pharmacokinetics, Serotonin Uptake Inhibitors/therapeutic use, Statistics, Nonparametric, Stereoisomerism, Substance-Related Disorders/blood, Substance-Related Disorders/rehabilitation
Web of science
Last modification date